Karyopharm Therapeutics | KPTI - Selling And Administration Expenses


Karyopharm Therapeutics reported $10.42M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Abbott USD 4.27B 669M Sep/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Merck USD 2.86B 25M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.08B 163M Sep/2026
Novartis USD 3.08B 58M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Takeda JPY 271.71B 14.8B Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026